Lv33
210 积分 2022-12-08 加入
874eP First-line (1L) encorafenib + cetuximab + mFOLFOX6 in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) in China: Results from the phase III BREAKWATER study
3小时前
求助中
1787MO Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage ALK+ non-small cell lung cancer (NSCLC)
6小时前
求助中
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
10小时前
已完结
Ⅳ期原发性肺癌中国治疗指南（2024版）
1天前
已完结
胆道恶性肿瘤转化治疗专家共识（2025）
1天前
已完结
达拉非尼和曲美替尼联合方案相关性发热的管理
1天前
已完结
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
1天前
已完结
BRAF in non–small cell lung cancer: From molecular mechanisms to clinical practice
3天前
已完结
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
4天前
已完结
皖公网安备34019202002308
